Axsome Therapeutics, Inc. (AXSM): Operating Cash Flow
-$93.41M
Year ended 2025-12-31
-$71.26M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$93.41M | n/m | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | -$128.41M | n/m | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | -$145.08M | n/m | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | -$116.51M | n/m | 2025-02-18, From 2022-01-01 |
| 2021-12-31 | -$108.23M | n/m | 2024-02-23, From 2021-01-01 |
| 2020-12-31 | -$78.46M | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$46.38M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$30.05M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$26.47M | n/m | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | -$21.28M | n/m | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | -$7.44M | n/m | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | -$4.60M | n/a | 2017-03-07, From 2014-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | -$93.41M | n/m |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | -$24.77M | n/m |
| Opko Health, Inc. (OPK) | 2025-12-31 | -$178.54M | n/m |
| Insmed Inc (INSM) | 2025-12-31 | -$935.01M | n/m |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$466.00M | n/m |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $137.99M | +437.1% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $47.33M | -72.5% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $156.12M | -26.8% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | -$10.31M | n/m |
Compare AXSM, TGTX, OPK, INSM side by side · Screen every company in Pharmaceutical Preparations ↗